| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.1 | 0.007 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | -0.094 | 0.008 |
| mRNA | BAY 61-3606 | GDSC1000 | pan-cancer | AAC | -0.096 | 0.008 |
| mRNA | BRD-K52037352 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.009 |
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | -0.096 | 0.009 |
| mRNA | PHA-793887 | CTRPv2 | pan-cancer | AAC | -0.087 | 0.009 |
| mRNA | RO-3306 | GDSC1000 | pan-cancer | AAC | -0.096 | 0.009 |
| mRNA | THZ-2-102-1 | GDSC1000 | pan-cancer | AAC | -0.083 | 0.009 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | 0.11 | 0.01 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | -0.096 | 0.01 |